The FDA has allowed the use of GE Healthcare's SPECT imaging agent AdreView, also known as iobenguane I-123, in the evaluation of myocardial sympathetic innervation in patients with New York Heart Association class II or III heart failure and left-ventricular ejection fraction at or lower than 35%. The company said the agent has the potential to detect the likelihood that patients' heart failure will advance.

Related Summaries